Lyra Therapeutics, Inc. (NASDAQ:LYRA – Get Free Report) has been assigned a consensus rating of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.13.
LYRA has been the topic of a number of recent research reports. William Blair lowered shares of Lyra Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, May 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Lyra Therapeutics in a research report on Thursday, June 20th. HC Wainwright downgraded Lyra Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the company from $12.00 to $2.00 in a research note on Tuesday, May 7th. BTIG Research restated a “neutral” rating on shares of Lyra Therapeutics in a research note on Monday, May 6th. Finally, Jefferies Financial Group lowered shares of Lyra Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $10.00 to $0.50 in a research report on Tuesday, May 7th.
Read Our Latest Stock Analysis on LYRA
Institutional Inflows and Outflows
Lyra Therapeutics Stock Performance
Lyra Therapeutics stock opened at $0.28 on Wednesday. The company has a market capitalization of $16.87 million, a P/E ratio of -0.23 and a beta of 0.02. Lyra Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $6.79. The stock has a 50-day simple moving average of $1.25 and a 200-day simple moving average of $3.86.
Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) last posted its quarterly earnings data on Tuesday, April 30th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.09). The firm had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.40 million. Lyra Therapeutics had a negative net margin of 4,099.82% and a negative return on equity of 77.34%. As a group, analysts forecast that Lyra Therapeutics will post -1.18 earnings per share for the current year.
Lyra Therapeutics Company Profile
Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
See Also
- Five stocks we like better than Lyra Therapeutics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Most active stocks: Dollar volume vs share volume
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.